Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
J Clin Invest ; 133(8)2023 04 17.
Artículo en Inglés | MEDLINE | ID: mdl-37066881

RESUMEN

Insulin secretion by pancreatic ß cells is a dynamic and highly regulated process due to the central importance of insulin in enabling efficient utilization and storage of glucose. Multiple regulatory layers enable ß cells to adapt to acute changes in nutrient availability as well as chronic changes in metabolic demand. While epigenetic factors have been well established as regulators of chronic ß cell adaptations to insulin resistance, their role in acute adaptations in response to nutrient stimulation has been relatively unexplored. In this issue of the JCI, Wortham et al. report that short-term dynamic changes in histone modifications regulated insulin secretion and acute ß cell adaptations in response to fasting and feeding cycles. These findings highlight the importance of investigating whether other epigenetic mechanisms may contribute to acute physiologic adaptations in ß cells.


Asunto(s)
Resistencia a la Insulina , Células Secretoras de Insulina , Secreción de Insulina , Cebollas/metabolismo , Insulina/metabolismo , Glucosa/metabolismo , Resistencia a la Insulina/fisiología , Células Secretoras de Insulina/metabolismo
2.
NPJ Regen Med ; 6(1): 22, 2021 Apr 06.
Artículo en Inglés | MEDLINE | ID: mdl-33824346

RESUMEN

Endogenous ß cell regeneration could alleviate diabetes, but proliferative stimuli within the islet microenvironment are incompletely understood. We previously found that ß cell recovery following hypervascularization-induced ß cell loss involves interactions with endothelial cells (ECs) and macrophages (MΦs). Here we show that proliferative ECs modulate MΦ infiltration and phenotype during ß cell loss, and recruited MΦs are essential for ß cell recovery. Furthermore, VEGFR2 inactivation in quiescent ECs accelerates islet vascular regression during ß cell recovery and leads to increased ß cell proliferation without changes in MΦ phenotype or number. Transcriptome analysis of ß cells, ECs, and MΦs reveals that ß cell proliferation coincides with elevated expression of extracellular matrix remodeling molecules and growth factors likely driving activation of proliferative signaling pathways in ß cells. Collectively, these findings suggest a new ß cell regeneration paradigm whereby coordinated interactions between intra-islet MΦs, ECs, and extracellular matrix mediate ß cell self-renewal.

3.
Diabetes Obes Metab ; 19 Suppl 1: 124-136, 2017 09.
Artículo en Inglés | MEDLINE | ID: mdl-28880471

RESUMEN

The progressive loss of pancreatic ß-cell mass that occurs in both type 1 and type 2 diabetes is a primary factor driving efforts to identify strategies for effectively increasing, enhancing or restoring ß-cell mass. While factors that seem to influence ß-cell proliferation in specific contexts have been described, reliable stimulation of human ß-cell proliferation has remained a challenge. Importantly, ß-cells exist in the context of a complex, integrated pancreatic islet microenvironment where they interact with other endocrine cells, vascular endothelial cells, extracellular matrix, neuronal projections and islet macrophages. This review highlights different components of the pancreatic microenvironment, and reviews what is known about how signaling that occurs between ß-cells and these other components influences ß-cell proliferation. Future efforts to further define the role of the pancreatic islet microenvironment on ß-cell proliferation may lead to the development of successful approaches to increase or restore ß-cell mass in diabetes.


Asunto(s)
Comunicación Celular , Proliferación Celular , Microambiente Celular , Células Secretoras de Insulina/metabolismo , Islotes Pancreáticos/citología , Modelos Biológicos , Animales , Apoptosis , Diabetes Mellitus Tipo 1/metabolismo , Diabetes Mellitus Tipo 1/patología , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Mellitus Tipo 2/patología , Matriz Extracelular/inmunología , Matriz Extracelular/metabolismo , Matriz Extracelular/patología , Células Secretoras de Glucagón/citología , Células Secretoras de Glucagón/inmunología , Células Secretoras de Glucagón/metabolismo , Células Secretoras de Glucagón/patología , Humanos , Células Secretoras de Insulina/citología , Células Secretoras de Insulina/inmunología , Células Secretoras de Insulina/patología , Islotes Pancreáticos/irrigación sanguínea , Islotes Pancreáticos/inervación , Islotes Pancreáticos/patología , Macrófagos/citología , Macrófagos/inmunología , Macrófagos/metabolismo , Macrófagos/patología , Células Secretoras de Polipéptido Pancreático/citología , Células Secretoras de Polipéptido Pancreático/inmunología , Células Secretoras de Polipéptido Pancreático/metabolismo , Células Secretoras de Polipéptido Pancreático/patología , Células Secretoras de Somatostatina/citología , Células Secretoras de Somatostatina/inmunología , Células Secretoras de Somatostatina/metabolismo , Células Secretoras de Somatostatina/patología , Especificidad de la Especie
4.
Cell Metab ; 25(6): 1362-1373.e5, 2017 Jun 06.
Artículo en Inglés | MEDLINE | ID: mdl-28591638

RESUMEN

Decreasing glucagon action lowers the blood glucose and may be useful therapeutically for diabetes. However, interrupted glucagon signaling leads to α cell proliferation. To identify postulated hepatic-derived circulating factor(s) responsible for α cell proliferation, we used transcriptomics/proteomics/metabolomics in three models of interrupted glucagon signaling and found that proliferation of mouse, zebrafish, and human α cells was mTOR and FoxP transcription factor dependent. Changes in hepatic amino acid (AA) catabolism gene expression predicted the observed increase in circulating AAs. Mimicking these AA levels stimulated α cell proliferation in a newly developed in vitro assay with L-glutamine being a critical AA. α cell expression of the AA transporter Slc38a5 was markedly increased in mice with interrupted glucagon signaling and played a role in α cell proliferation. These results indicate a hepatic α islet cell axis where glucagon regulates serum AA availability and AAs, especially L-glutamine, regulate α cell proliferation and mass via mTOR-dependent nutrient sensing.


Asunto(s)
Proliferación Celular , Glucagón/metabolismo , Glutamina/metabolismo , Hígado/metabolismo , Transducción de Señal , Sistemas de Transporte de Aminoácidos Neutros/genética , Sistemas de Transporte de Aminoácidos Neutros/metabolismo , Animales , Glucagón/genética , Glutamina/genética , Ratones , Ratones Noqueados , Pez Cebra , Proteínas de Pez Cebra/genética , Proteínas de Pez Cebra/metabolismo
5.
Am J Physiol Endocrinol Metab ; 311(5): E859-E868, 2016 11 01.
Artículo en Inglés | MEDLINE | ID: mdl-27624103

RESUMEN

Numerous compounds stimulate rodent ß-cell proliferation; however, translating these findings to human ß-cells remains a challenge. To examine human ß-cell proliferation in response to such compounds, we developed a medium-throughput in vitro method of quantifying adult human ß-cell proliferation markers. This method is based on high-content imaging of dispersed islet cells seeded in 384-well plates and automated cell counting that identifies fluorescently labeled ß-cells with high specificity using both nuclear and cytoplasmic markers. ß-Cells from each donor were assessed for their function and ability to enter the cell cycle by cotransduction with adenoviruses encoding cell cycle regulators cdk6 and cyclin D3. Using this approach, we tested 12 previously identified mitogens, including neurotransmitters, hormones, growth factors, and molecules, involved in adenosine and Tgf-1ß signaling. Each compound was tested in a wide concentration range either in the presence of basal (5 mM) or high (11 mM) glucose. Treatment with the control compound harmine, a Dyrk1a inhibitor, led to a significant increase in Ki-67+ ß-cells, whereas treatment with other compounds had limited to no effect on human ß-cell proliferation. This new scalable approach reduces the time and effort required for sensitive and specific evaluation of human ß-cell proliferation, thus allowing for increased testing of candidate human ß-cell mitogens.


Asunto(s)
Proliferación Celular/efectos de los fármacos , Células Secretoras de Insulina/efectos de los fármacos , Activinas/farmacología , Adenosina/análogos & derivados , Adenosina/farmacología , Agonistas del Receptor de Adenosina A2/farmacología , Adenosina-5'-(N-etilcarboxamida)/farmacología , Adulto , Automatización , Técnicas de Cultivo de Célula , Evaluación Preclínica de Medicamentos , Eritropoyetina/farmacología , Exenatida , Femenino , GABAérgicos/farmacología , Harmina/farmacología , Humanos , Incretinas/farmacología , Masculino , Persona de Mediana Edad , Inhibidores de la Monoaminooxidasa/farmacología , Miostatina/farmacología , Nucleósidos/farmacología , Péptidos/farmacología , Factor de Crecimiento Derivado de Plaquetas/farmacología , Prolactina/farmacología , Regeneración/efectos de los fármacos , Serotonina/farmacología , Agonistas de Receptores de Serotonina/farmacología , Vasodilatadores/farmacología , Ponzoñas/farmacología , Adulto Joven , Ácido gamma-Aminobutírico/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA